Status:
COMPLETED
Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lead Sponsor:
University of Monastir
Conditions:
COPD Exacerbation
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
Treatment with short acting β2 agonists for exacerbations of COPD results in clinical improvement. It has not been established whether combining short acting β2 agonists to other bronchodilators is mo...
Detailed Description
Patients presenting to the emergency department with exacerbation of COPD are randomized to receive nebulised ipratropuim bromide or combined nebulised and an intravenous bolus of magnesium sulfate du...
Eligibility Criteria
Inclusion
- 40 years old or over
- have known or suspected COPD based on pulmonary function test, arterial blood gas, clinical history, physical examination, and chest radiograph
- worsening of dyspnea within 2 weeks,
- partial pressure of arterial carbon dioxide (PaCO2) \>45 mmHg
- respiratory rate \>24/min
- arterial pH \<7.35
- partial pressure of arterial oxygen (PaO2) \<50 mmHg under room air
Exclusion
- hypersensitivity to anticholinergics and to magnesium sulfate
- patients that received anticholinergics within 6 hours before ED admission
- systolic arterial pressure \<90 mmHg or need to vasoactive drugs
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT01136421
Start Date
January 1 2005
End Date
June 1 2007
Last Update
June 3 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Monastir
Monastir, Monstir, Tunisia, 5000
2
Soudani Marghli
Mahdia, Tunisia, Tunisia, 5100